

Gibson Dunn Advises XOMA Royalty on Acquisition of Generation Bio Co.

Firm News | December 18, 2025

Gibson Dunn is representing XOMA Royalty Corporation, a publicly traded biotech royalty aggregator, on its acquisition of Generation Bio Co. (Nasdaq: GBIO), a biopharmaceutical company that was focused on developing treatment technology for people living with T-cell driven autoimmune diseases.

Gibson Dunn regularly advises life sciences companies and investors on complex mergers and acquisitions in the biotechnology sector.

The Gibson Dunn corporate team includes Ryan Murr, Branden Berns, Lauren Guzman, and Lauren Romagnoli. Team members advising on additional aspects of the transaction include Pamela Lawrence Endreny (tax), Sean Feller and Spencer Bankhead (employee benefits), and Charlotte Jacobsen and Monica Grover (IP).

Related People

[Ryan A. Murr](#)

[Branden C. Berns](#)

[Lauren Guzman](#)

[Lauren Romagnoli](#)

[Pamela Lawrence Endreny](#)

[Sean C. Feller](#)

[Spencer Bankhead](#)

[Charlotte Jacobsen](#)

[Monica Grover](#)

Related Capabilities

[Mergers and Acquisitions](#)

[Life Sciences](#)

[Tax](#)

[Executive Compensation and Employee Benefits](#)

[Intellectual Property](#)